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Abstract
Background: Pfeifer-Weber-Christian disease (PWCD) is a rare inflammatory disorder of the subcutaneous fatty
tissue. The diagnosis and therapy of this rare type of panniculitis is still controversial and will be discussed in this
article.
Case presentation: We here report the rare case of a 64-year old male patient, with PWCD. The patient suffered
from rheumatoid arthritis for several years, but then developed relapsing fever and recently occurring painful
subcutaneous nodules predominantly at the inner part of his left upper limb with no signs of synovitis. Finally, a
biopsy from one of the nodules revealed lobular panniculitis with mixed cell infiltrate, which was conformable only
with PWCD, after excluding several differential diagnoses. In our patient PWCD developed despite
immunosuppressive therapy with steroids and different disease modifying drugs, which the patient received to
treat his underlying rheumatoid arthritis. However, when DMARD therapy was switched to Ciclosporin A the
patient’s symptoms resolved.
Conclusion: Our observation supports the hypothesis that T cells are involved in the pathogenesis of PWCD. Thus,
T cell modifying drugs should be primarily used to treat patients with this rare disorder.
Background
Pfeifer-Weber-Christian Disease (PWCD) is a rare
inflammatory disorder of subcutaneous adipose tissue. It
is also known as ideopathic relapsing febrile lobular
non-suppurative panniculitis and is characterized by
recurrent subcutaneous inflammatory painful nodules,
fever, and malaise due to systemic inflammation. PWCD
is an exclusion diagnosis, when no other cause of the
lobular panniculitis can be identified. The most impor-
tant other causes of lobular panniculitis include systemic
lupus erythematosus, a1-antitrypsin deficiency, lym-
phoma, trauma, pancreatitis, and certain types of infec-
tions (for review see [1,2]). The characteristic painful
nodules are observed primarily in the area of the lower
extremities and the trunk. It is still debated if PWCD
exists as a unique disease entity or if it is just a substi-
tute for any lobular panniculitis with unknown cause.
The reason for this debate is that, having more medical
knowledge and better diagnostic tools, many of the
cases of idiopathic lobular panniculitis diagnosed with
so-called PWCD have other underlying causes [1,3,2].
However, we here present the case of a 64-year old
male patient with relapsing febrile lobular non-suppura-
tive panniculitis with mixed cell infiltrate of unknown
origin. Even after extensived i a g n o s t i cp r o c e d u r e sw e
could not identify any of the known causes of lobular
panniculitis. We therefore diagnosed a PWCD and suc-
cessfully treated the patient with Cyclosporin A. The
case supports the hypothesis that PWCD is a T cell
mediated autoinflammatory condition.
Case presentation
Here, we report the rare case of a 64-year old male
patient with rheumatoid arthritis, relapsing fever and
recently occurring painful subcutaneous nodules predo-
minantly at the inner part of his left upper limb.
On first encounter with the patient in 2007, he
reported symptoms of arthritis with varying intensity
since 1992. However, till 2003 he did not receive any
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nosed with RF positive, anti-CCP antibody negative
rheumatoid arthritis (RA), which was initially treated
with methotrexate (MTX) and prednisolone. However,
therapy with MTX was discontinued after a few weeks
due to unspecific malaise. In early 2007, the patient was
referred to our Department with an acute flare of RA
(Figure 1). The acute symptoms were successfully trea-
ted with prednisolone. Additional disease modifying
anti-rheumatic drug (DMARD) therapy with leflunomide
was initiated, which was well tolerated by the patient,
except for mild edema of his lower legs. About half a
year later, the patient presented again with highly ele-
vated humoral inflammatory parameters (Figure 1) and
pain on exertion in both hips, knees and ankles with
swelling of the latter two as well as several MCP joints.
At this time, there were no fever or night sweats, and
the patient had gained 10 kg of body weight after his
last admission. Again, prednisolone treatment was
started (max. 20 mg/d) leading to rapid improvement.
In addition, low dose subcutaneous MTX therapy was
added to leflunomide. On routine check-up after 6
month, the patient had no joint pain or swelling and no
signs of synovitis by ultrasonography. However, humoral
inflammatory activity was still high (Figure 1), and the
patient described his general condition as “deteriorating”
with fever, night sweats and loss of body weight. He
additionally complained about paresthesia and pain on
pressure in both feet and lower legs. Despite compre-
hensive diagnostic evaluation including echocardiogra-
phy, sonography of joints, soft tissue and abdomen,
computed-tomography of the thorax, repeated blood
cultures, bone marrow aspiration and urine testing, we
were not able to identify any infectious or malignant
cause for the patients deterioration. Also, values for
ANA, ANCA, anti-ds-DNA, complement factors C3 and
C4, anti-CCP, and anti-MCV were within the normal
range or not detectable, respectively. RF was positive,
but has been positive since the diagnosis of RA in 2003.
Due to extremely pressure sensitive skin of the lower
limbs skin-biopsies were obtained, which revealed an
unspecific chronic fibrosing inflammation. Furthermore,
a positron emission tomography with fluorodeoxyglu-
cose (FDG-PET) was performed, which demonstrated
focal areas of increased glucose uptake on the lower
limbs but did not show a typical vasculitis pattern. On a
repeated thorough clinical examination, new small (< 5
mm) subcutaneous nodules could be palpated mainly at
the inner side of the thighs. However, those lesions
could not be detected by ultrasonography. Thus, no
biopsy was taken at that time. Treatment with MTX
was stopped and replaced by sulfasalazine (Figure 1).
Following treatment with high dose prednisolone, the
patient’s condition improved significantly and CRP levels
decreased rapidly (Figure 1). However, one month later
the patient presented in deteriorated condition with
high inflammatory parameters (CRP 220 mg/l, Figure 1).
He presented with high fever (up to 40°C), lasting for
several days, night sweats and increasing painful nodular
lesions (3 - 4 cm) at the inner side of the thighs that led
to a complete immobilisation of the patient due to pain.
On first sight, the lesions appeared as an erythema
nodosum, only with less apparent skin discoloration.
With regard to the joints, the patient had no complaints
and physical examination revealed no signs of synovitis.
One of the painful nodules was removed for histological
analysis. An MRI-scan of the lower limbs revealed signs
of acute fasciitis. After exclusion of any infectious or
malignant cause, the patient was again treated with high
dose prednisolone (80 mg/d, i.v.). The histology of the
nodule revealed a lobular panniculitis, with a mixed cell
infiltrate dominated by neutrophils (Figure 2). Together
with the clinical findings with a strong systemic inflam-
matory response without any indication of a flare of the
rheumatoid arthritis or underlying infectious or malig-
nant cause, we established the diagnosis of a Pfeifer-
Weber-Christian disease (PWCD). Leflunomide and sul-
fasalazine were therefore replaced by cyclosporine A.
The patient responded well to this treatment and tem-
perature as well as inflammatory markers returned back
to normal levels rapidly (Figure 1). The patient could be
discharged from the hospital. On a routine check-up in
the following month the patient presented in very good
general condition with no more signs of inflammation.
The nodules were still present but clearly reduced in
size, and the patient only reported minor pain on
pressure.
Discussion
Here, we report the rare case of a Pfeifer-Weber-Chris-
tian syndrome, which responded well to therapy with
prednisolone and cyclosporine A.
The diagnosis of a Pfeifer-Weber-Christian disease
(PWCD) is depending on the presence of relapsing
fever, systemic inflammation and panniculitis. However,
due to the rarity of this condition it is still under debate,
if PWCD is a unique disease entity, or if it is just a sub-
stitute for every panniculitis that does not fit a common
diagnosis [3]. This uncertainty might be the result of the
fact that this disease entity has not been described in a
monolithic way, and the original cases reported by Pfei-
fer, Weber and Christian differed slightly from each
other [4]. Pfeifer in 1892 first described multiple areas
of atrophy in subcutaneous fatty tissue with no further
specification [4]. Weber described a “relapsing, non-sup-
purative panniculitis” in 1925 [5], and Christian in 1928
pointed out its febrile character [6]. However, this can
also be regarded as a process of refining symptoms
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Page 2 of 5Figure 1 Schematic time course of C-reactive protein levels and concurrent therapy. Dashed-line: Prednisolone (mg/d); solid-line: CRP (mg/l).
CRP: C-reactive protein; RA: rheumatoid arthritis; GC: general condition; LEF: leflunomide; MTX: methotrexate; SLZ: sulfasalazine; CyA: cyclosporine
A.
Figure 2 Histology (painful node, left lower leg). Standard histological processing was performed on a painful node obtained from the lower
limb. Two HE-stained sections at different magnifications (left 20×, right 30×) are depicted. The sections show predominantly lobular panniculitis
with mixed inflammatory cell infiltration.
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inflammation and lobular panniculitis of relapsing char-
acter, to finely define PWCD. With respect to the histo-
logical findings in panniculitis, an attempt was made to
categorize nodular panniculitis into different histologi-
cally defined subtypes according to the pattern and
composition of the inflammatory infiltrate [7]. PWCD
has been classified as lobular panniculitis with mixed
cell infiltrate, which contrasts findings in erythema
nodosum classified as predominantly septal panniculitis
[7].
Unfortunately, in several reported cases the diagnosis
of PWCD was solely based on histological findings [3].
However, in our opinion diagnosis should always be
based on clinical and histological findings, which might
facilitate the recognition of PWCD as unique disease
entity. Of course, the described symptoms together with
lobular panniculitis can also occur in other diseases
such as infections, certain malignancies, alpha-1-anti-
trypsin deficiency, pancreatitis, systemic lupus erythema-
tosus and cytophagic histiocytic panniculitis, rendering
PWCD an exclusion diagnosis following careful evalua-
tion of the patient. However, all of these disease entities,
except alpha-1-antitrypsin deficiency, were excluded in
our patient by extensive diagnostic evaluation favouring
the diagnosis of a PWCD (see above). We did not expli-
citly exclude alpha-1-antitrypsin deficiency, because pan-
niculitis is only observed in patients with severe forms
of the disease [2,8], which would include other symp-
toms, like COPD and/or liver cirrhosis. However, our
patient didn’t show these symptoms and responded well
to immunosuppressive therapy, which would not
improve panniculitis due to alpha-1-antitrypsin
deficiency.
Treatment of PWCD is also controversial, which
might again be attributed to the fact that clear diagnos-
tic criteria have not yet been established. Thus, it does
not surprise that there are several treatment options
r e p o r t e di nt h el i t e r a t u r em o s t l yi nt h ef o r mo fc a s e
reports. However, the best evidence exists for cyclospor-
ine A and corticosteroids [9-17]. Our patient improved
rapidly following cyclosporine A and corticosteroid
treatment. Cyclosporine A is classified as a calcineurin
inhibitor predominantly inhibiting IL-2 production and
transduction of antigen-recognition signals in activated
T cells [18]. In the here reported case, leflunomide,
methotrexate and sulfasalazine, despite displaying a
broader range of immunosuppressive activity by inter-
acting with multiple signaling pathways in various cell
types, were not effective [18]. Thus, even though the
pathogenesis of PWCD is not finally resolved, the fact
that the patient only responded to cyclosporine A points
towards a predominant involvement of T-cells in the
disease process.
Conclusion
In conclusion, this case report supports the hypothesis
that PWCD is a T-cell mediated inflammatory disorder.
Therefore, in our opinion, patients with PWCD should
primarily be treated with T-cell modifying agents. How-
ever, it is still controversial if PWCD exists as a separate
disorder or if the characteristic symptoms and inflam-
matory patterns are just a m a n i f e s t a t i o no fa no t h e r
underlying cause. Therefore, consideration of PWCD
has to be based on a broad diagnostic procedure to
exclude all likely differential diagnoses of lobular panni-
culitis, like infections, certain malignancies, alpha-1-anti-
trypsin deficiency, pancreatitis, systemic lupus
erythematosus and cytophagic histiocytic panniculitis.
Patient’s consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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